- The shares of oncology-focused Ideaya Biosciences Inc (NASDAQ: IDYA) are trading higher after interim data from its solid tumor candidate darovasertib with cancer therapy crizotinib in patients with metastatic uveal melanoma (MUM).
- Interim results confirmed partial responses in four out of eight evaluable patients, or an overall response rate of 50%, in first-line metastatic uveal melanoma patients.
- 89% of patients showed tumor shrinkage in any-line metastatic uveal melanoma patients, the company said.
- 15 of 35 evaluable patients observed partial responses with >30% tumor reduction, including 11 confirmed and four unconfirmed partial responses.
- 50% of the overall response rate was observed, with 4 of 8 evaluable patients having a confirmed partial response (PR).
- Meanwhile, the median progression-free survival has not yet been reached in first-line metastatic uveal melanoma patients, while median progression-free survival is around five months for any-line metastatic uveal melanoma patients.
- The company plans to launch a potential registration-enabling trial in Q1 2023.
- Price Action: IDYA shares are up 26.40% at $11.69 on the last check Monday.
US Stocks Could Continue Momentum 3rd Day Straight As Earnings Drive Nasdaq, S&P 500 Futures Higher — Netflix, Tesla, Chip-Equipment Stocks In Focus
The U.S. index futures point to a higher opening by stocks on Wednesday following the strong runup seen in the previous two sessions.
